Valeo Financial Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 14.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,715 shares of the company's stock after selling 4,519 shares during the period. Valeo Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $1,925,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in Novo Nordisk A/S by 8.1% during the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after acquiring an additional 1,165,955 shares during the last quarter. GQG Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Renaissance Technologies LLC grew its stake in Novo Nordisk A/S by 1.5% during the 4th quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock worth $715,084,000 after buying an additional 123,681 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its position in Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after buying an additional 2,639,693 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts have weighed in on the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $112.00.
Read Our Latest Research Report on Novo Nordisk A/S
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S stock traded up $1.37 during midday trading on Thursday, hitting $71.06. 6,372,154 shares of the company were exchanged, compared to its average volume of 7,305,346. The business has a fifty day simple moving average of $70.25 and a two-hundred day simple moving average of $75.33. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The firm has a market capitalization of $317.26 billion, a PE ratio of 21.02, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $143.49.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion for the quarter. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.
Novo Nordisk A/S Company Profile
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
